Edwards Lifesciences (EW) and ResMed (RMD) on Torvanta's measures: EW grades higher on 1 of the 4 factor families and RMD on 2.
| EW | RMD | |
|---|---|---|
| Value grade | D+ | C |
| Growth grade | B | C |
| Profitability grade | B | B+ |
| Momentum grade | C- | C- |
| Market value | $49.9B | $34.5B |
| P/E (trailing) | 49.8x | 22.9x |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $6.5B | $5.7B |
| Revenue growth (y/y) | +15% | +10% |
| Operating margin | 22.3% | 33.4% |
| Return on invested capital | 12.0% | 25.9% |
| Free-cash-flow yield | 2.9% | 4.8% |
| Total return, 1 year | +19.2% | -10.5% |
| Total return, 3 years | +21.5% | +74.3% |
Full EW analysis · Full RMD analysis
Edwards Lifesciences (EW) and ResMed (RMD) on Torvanta's measures: EW grades higher on 1 of the 4 factor families and RMD on 2. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings EW trades at 49.8x and RMD at 22.9x; their value grades are D+ and C against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer